# Sample Evidence-Backed Founder Diagnosis > **This is a sample, not a real customer case.** The product and funnel numbers below are fictional so no private founder data is exposed. The market evidence and competitor pricing were checked against public sources on **2026-09-09**. ## Case snapshot **Product:** MeetFlow — AI meeting notes for freelancers, with automatic task extraction and follow-up reminders. **Current offer:** $12/month after a free trial. **Observed funnel (fictional):** - 480 landing-page visits - 62 signups - 28 connected a calendar - 17 recorded at least 3 meetings - 0 paid upgrades - 9 user conversations - 6 said the notes were useful - 5 already used another meeting-notes tool - 4 said task sync was “nice” but not enough reason to switch **Founder hypothesis:** “Maybe $12/month is too expensive. Should I cut it to $5?” **Decision needed in 7 days:** Lower price, keep building features, or change positioning. --- ## Root-cause diagnosis **Most likely bottleneck: insufficient switching value, not price.** The product is getting enough activation to show that onboarding is not the first thing to fix: 17 people used it repeatedly. But none paid, and the interviews say several users already have a substitute. The strongest evidence against the “price is too high” hypothesis is the current market itself: comparable meeting-note products charge in roughly the same range while also offering strong free tiers. The immediate problem is therefore not “can people afford $12?” It is “why should an already-satisfied user switch from a free or established substitute?” ### External evidence 1. **Granola** currently offers a $0 Basic tier and a **$14/user/month Business** plan with unlimited meeting history, advanced models, integrations, MCP and API access. Source: https://www.granola.ai/pricing 2. **Fireflies.ai** currently offers a free tier with unlimited transcription and limited AI summaries. Its Pro plan is **$10/user/month billed annually** or **$18 monthly**. Source: https://fireflies.ai/pricing 3. **Fathom** is still known for a generous free tier with unlimited recordings/transcription/storage for one person; current paid entry pricing is around **$16/user/month** according to a 2026 comparison that links to the live products. Source: https://fireflies.ai/blog/fireflies-vs-fathom ### What this evidence means - $12/month is not obviously outside the category’s normal paid range. - The category gives solo users strong free substitutes. - A new entrant therefore needs a **specific outcome wedge** that the free incumbents do not already satisfy, not just cheaper generic notes. So cutting the price to $5 would probably make the business weaker without answering the switching question. --- ## Contradiction check This diagnosis would be wrong if one of the following turns out to be true: - The 17 activated users actually love the product but are blocked by a broken checkout or payment flow. - A meaningful share explicitly says they would buy at $5 but not at $12. - Users who do **not** already use a competitor convert materially better than switchers. Those are testable within a week. --- ## 7-day experiment plan ### Test 1 — Separate “switchers” from “no-tool” users Ask all 17 activated users one factual question: **“What did you use for meeting notes before MeetFlow?”** Track two cohorts: - already using Granola / Fireflies / Fathom / another substitute - no prior dedicated tool **Pass signal:** no-tool users show at least 2× the willingness to pay of switchers. **Meaning:** acquisition should target people without an incumbent, not steal satisfied users. ### Test 2 — Sell an outcome, not meeting notes Do not build a feature yet. Put one narrow promise in front of the activated users, for example: > “After every client call, get a ready-to-send follow-up plus an invoice/action checklist — without editing meeting notes.” Offer the result at the existing $12/month price to the 17 activated users. **Pass signal:** at least **2 paid commitments** from the activated cohort. **Fail signal:** 0 paid commitments despite direct exposure to the narrow outcome. ### Test 3 — Price only after value is isolated If Test 2 gets interest but objections are specifically about price, test $8 vs. $12 with the same outcome and no other changes. **Do not run this test first.** A price test before a value test confounds “too expensive” with “not valuable enough.” --- ## Kill / continue rule **Continue** if at least 2 of the 17 activated users commit to pay for one narrow post-meeting outcome, even if the feature must initially be delivered manually. **Kill the current positioning** if 0 of 17 will commit after seeing a specific outcome that goes beyond generic notes. Do not spend the next month polishing transcription, summaries, or task extraction that incumbents already give away. --- ## The decision **Do not cut the price yet. Do not build another generic meeting feature.** Spend the next 7 days testing whether there is a narrow workflow outcome strong enough to make an activated user switch or pay. That is the kind of decision the paid OPC Clinic diagnosis is designed to produce: one bottleneck, current outside evidence, explicit disconfirming evidence, and a short test with a kill rule.